Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Osteoarthritis Therapeutics Market 

5.1. COVID-19 Landscape: Osteoarthritis Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Osteoarthritis Therapeutics Market, By Drugs

8.1. Osteoarthritis Therapeutics Market, by Drugs, 2023-2032

8.1.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Viscosupplementation agents

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Corticosteroids

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Hyaluronic Acid Injection

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Analgesics

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Osteoarthritis Therapeutics Market, By Anatomy

9.1. Osteoarthritis Therapeutics Market, by Anatomy, 2023-2032

9.1.1. Ankle Osteoarthritis

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Hip Osteoarthritis

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Knee Osteoarthritis

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Shoulder Osteoarthritis

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Osteoarthritis Therapeutics Market, By Purchasing Pattern 

10.1. Osteoarthritis Therapeutics Market, by Purchasing Pattern, 2023-2032

10.1.1. Prescription Drugs

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Over-the-counter Drugs

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Osteoarthritis Therapeutics Market, By Distribution Channel

11.1. Osteoarthritis Therapeutics Market, by Distribution Channel, 2023-2032

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Hypermarket & Supermarket

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Retail Pharmacies

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Osteoarthritis Therapeutics Market, By Route of Administration

12.1. Osteoarthritis Therapeutics Market, by Route of Administration, 2023-2032

12.1.1. Parenteral Route

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Topical Route

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Oral Route

12.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Osteoarthritis Therapeutics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.1.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.1.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.6.5. Market Revenue and Forecast, by Route of Administration (2020-2032) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.1.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.7.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.2.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.2.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032) 

13.2.5. Market Revenue and Forecast, by Route of Administration (2020-2032) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.2.7. Market Revenue and Forecast, by Distribution Channel (2020-2032) 

13.2.8. Market Revenue and Forecast, by Route of Administration (2020-2032) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.2.10. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.11. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.2.12.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.13. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.2.14.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.15. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.3.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.3.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.9. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.3.10.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.10.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.3.11.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.11.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.4.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.4.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.9. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.4.10.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.10.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.4.11.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.11.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.5.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.5.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.7. Market Revenue and Forecast, by Route of Administration (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Drugs (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)

13.5.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.8.5. Market Revenue and Forecast, by Route of Administration (2020-2032)

Chapter 14. Company Profiles

14.1. Abbott Laboratories

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. ABIOGEN PHARMA S.p.A

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Ampio Pharmaceuticals Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Anika Therapeutics Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bayer Aktiengesellschaft

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Bioventus

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Eli Lilly and Company.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Ferring B.V.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Flexion Therapeutics, Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. GlaxoSmithKline Plc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms